GGrantIndex
← Search

Proteomics and Metabolomics Shared Resource

$33,142P30FY2022CANIH

Wake Forest University Health Sciences, Winston-Salem NC

Investigators

Linked publications, trials & patents

Trial NCT07614022Trial NCT07324577Trial NCT07322367Trial NCT07282444Trial NCT07203534Trial NCT07196241Trial NCT07175376Trial NCT07119489Trial NCT07046936Trial NCT06945042Trial NCT06709404Trial NCT06654245Trial NCT06480591Trial NCT06441266Trial NCT06340503Trial NCT05984680Trial NCT05934851Trial NCT05877404Trial NCT05854966Trial NCT05825066Trial NCT05796518Trial NCT05696782Trial NCT05692635Trial NCT05597878Trial NCT05395936Trial NCT05309655Trial NCT05242770Trial NCT05212272Trial NCT05204290Trial NCT05030038Trial NCT04897217Trial NCT04858269Trial NCT04797884Trial NCT04677816Trial NCT04659993Trial NCT04623515Trial NCT04586127Trial NCT04526080Trial NCT04495751Trial NCT04485026Trial NCT04454489Trial NCT04430335Trial NCT04415944Trial NCT04375384Trial NCT04337580Trial NCT04327700Trial NCT04266470Trial NCT04253964Trial NCT04217317Trial NCT04174742Trial NCT04173247Trial NCT04111107Trial NCT04040244Trial NCT04037527Trial NCT03998189Trial NCT03987568Trial NCT03987555Trial NCT03982537Trial NCT03963739Trial NCT03958747Trial NCT03929211Trial NCT03890614Trial NCT03880526Trial NCT03874065Trial NCT03870529Trial NCT03870451Trial NCT03868943Trial NCT03867175Trial NCT03861091Trial NCT03861065Trial NCT03796273Trial NCT03746262Trial NCT03741868Trial NCT03741829Trial NCT03740035Trial NCT03681405Trial NCT03662074Trial NCT03529565Trial NCT03520283Trial NCT03505762Trial NCT03505736Trial NCT03505671Trial NCT03379376Trial NCT03374995Trial NCT03370159Trial NCT03188432Trial NCT03152786Trial NCT03148080Trial NCT03139435Trial NCT03122743Trial NCT03087591Trial NCT03032250Trial NCT02971410Trial NCT02971397Trial NCT02949843Trial NCT02835222Trial NCT02835066Trial NCT02832154Trial NCT02827838Trial NCT02747407

Abstract

PROTEOMICS AND METABOLOMICS SHARED RESOURCE (PMSR): PROJECT SUMMARY The Proteomics and Metabolomics Shared Resource (PMSR) provides advanced mass spectrometry services, technologies, data analysis, and scientific consultation for global and targeted proteomics, metabolomics, and lipidomics to support Wake Forest Baptist Comprehensive Cancer Center (WFBCCC) efforts in precision oncology—one of the Cancer Center’s top strategic priorities. More broadly, PMSR specializes in discovery, identification, characterization, and quantification of biomolecules, drugs, and biologically active natural compounds by mass spectrometry and biochemical methods, and chromatography of proteins, peptides, lipids, and nucleic acids. Technology assets of PMSR include a Thermo Q-Exactive HF with Vanquish UHPLC for metabolomics and lipidomics services, a Shimadzu LCMS-8050 Triple Quadrupole, and a SCIEX Triple Quad™ 6500+ LC-MS/MS System for targeted analysis of small molecules (drugs, metabolites, natural products), a Thermo Orbitrap Velos Pro w/ETD MS with UltiMate™ 3000 RSLCnano system for proteomics, and a series of HPLC systems with UV-VIS and fluorescence detection. PMSR also has access to MS instruments in the Center for Precision Medicine (e.g., Thermo Orbitrap Fusion Lumos Tribrid and Thermo GC Q-Exactive HF mass spectrometers) and instruments in the PMSR Co-Director’s personal laboratory (Agilent 6120 MSD ESI-TOF MS). The institution has scheduled the acquisition of a Thermo Scientific Orbitrap Eclipse w/ETD for the PMSR in the first quarter of FY22 (07/2021). Expertise and technical support for metabolic flux studies are provided in partnership with the University of Kentucky Resource Center for Stable Isotope-Resolved Metabolomics (one of the resource centers funded by the NIH Common Fund and associated with the NCI-Designated Markey Cancer Center). PMSR is directed by Cristina Furdui, PhD, and Mark Lively, PhD, and is supported by five highly trained staff. Over the recent years, the Wake Forest School of Medicine and WFBCCC provided critical support to maintain high-quality operations in the PMSR, contributing $108,965 to match the $200,000 awarded by North Carolina Biotechnology Center for the purchase of the Shimadzu LCMS-8050 mass spectrometer in 2017, $46,708 to purchase a new Vanquish UHPLC system in 2018, and $6,230 to purchase the Sigma Mass Spectrometry Metabolite Library. PMSR is managed by WFBCCC and is supported financially by the CCSG, the Wake Forest School of Medicine, and a chargeback mechanism. During the reporting period, the PMSR supported the research of 31 WFBCCC users (up from 17 reported at the previous CCSG renewal); 41 cancer grants; 5 clinical studies; and 30 publications. Total usage since 2016 corresponded to 33,291 hours (19,627 fee-for-service, 9,109 for development of new methods, and 4,555 for quality control and optimization).

View original record on NIH RePORTER →